MX2018003619A - Tratamiento de enfermedades neurodegenerativas. - Google Patents
Tratamiento de enfermedades neurodegenerativas.Info
- Publication number
- MX2018003619A MX2018003619A MX2018003619A MX2018003619A MX2018003619A MX 2018003619 A MX2018003619 A MX 2018003619A MX 2018003619 A MX2018003619 A MX 2018003619A MX 2018003619 A MX2018003619 A MX 2018003619A MX 2018003619 A MX2018003619 A MX 2018003619A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- signalling
- methods
- neurodegenerative diseases
- inhibitor
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 230000011664 signaling Effects 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 abstract 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1516905.5A GB201516905D0 (en) | 2015-09-24 | 2015-09-24 | Treatment of Neurodegenerative diseases |
| PCT/GB2016/052970 WO2017051188A1 (en) | 2015-09-24 | 2016-09-23 | Treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018003619A true MX2018003619A (es) | 2018-08-01 |
Family
ID=54544061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003619A MX2018003619A (es) | 2015-09-24 | 2016-09-23 | Tratamiento de enfermedades neurodegenerativas. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180263992A1 (enExample) |
| EP (1) | EP3352759A1 (enExample) |
| JP (1) | JP6893917B2 (enExample) |
| KR (1) | KR20180056695A (enExample) |
| CN (1) | CN108025005A (enExample) |
| AU (1) | AU2016329005A1 (enExample) |
| BR (1) | BR112018005855A2 (enExample) |
| CA (1) | CA2999390A1 (enExample) |
| EA (1) | EA201890647A1 (enExample) |
| GB (1) | GB201516905D0 (enExample) |
| MA (1) | MA42930A (enExample) |
| MX (1) | MX2018003619A (enExample) |
| WO (1) | WO2017051188A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016077595A1 (en) | 2014-11-12 | 2016-05-19 | The General Hospital Corporation | Methods for treating neurodegenerative diseases |
| GB201714307D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatment of neurodegenerative diseases |
| GB201714311D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatment of neurodegenerative diseases |
| GB201714316D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatement of neurodegenerative diseases |
| GB201714303D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatment of neurodegenerative diseases |
| CN108853111B (zh) * | 2018-08-07 | 2020-06-05 | 浙江大学 | 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用 |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| CN113694047A (zh) * | 2021-08-31 | 2021-11-26 | 杭州师范大学 | β-石竹烯在制备抗肿瘤药物中的应用 |
| WO2025152803A1 (zh) * | 2024-01-17 | 2025-07-24 | 四川大学 | 一种靶向traf6的多肽及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US257403A (en) * | 1882-05-02 | Electric lighting apparatus | ||
| US62342A (en) * | 1867-02-26 | Improved tool for the manufacture of paper bags | ||
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| CA2484797A1 (en) * | 2002-05-06 | 2003-11-13 | Washington University | Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway |
| JP4328500B2 (ja) * | 2002-07-25 | 2009-09-09 | 独立行政法人農業・食品産業技術総合研究機構 | 中枢神経細胞突起再生剤及びその薬理作用を有する高機能性製品 |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| JP2006522124A (ja) * | 2003-04-03 | 2006-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用な組成物 |
| ES2673158T3 (es) * | 2004-02-09 | 2018-06-20 | Mitsubishi Tanabe Pharma Corporation | Nuevo agente terapéutico para la esclerosis lateral amiotrófica (ELA) o enfermedad atribuible a ELA |
| RU2405566C9 (ru) * | 2005-02-03 | 2012-04-27 | Дзе Дженерал Хоспитал Корпорейшн | Способ лечения рака, устойчивого к гефитинибу |
| US7449442B2 (en) * | 2005-07-12 | 2008-11-11 | Children's Medical Center Corporation | EGFR inhibitors promote axon regeneration |
| JP2008061505A (ja) * | 2006-09-04 | 2008-03-21 | Hisamitsu Pharmaceut Co Inc | 筋萎縮性側索硬化症の治療剤のスクリーニング方法 |
| US8993615B2 (en) * | 2008-08-08 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for treatment of neurodegenerative disease |
| CN102573500A (zh) * | 2009-08-06 | 2012-07-11 | 纽拉尔图斯制药公司 | 巨噬细胞相关疾病的治疗 |
| EP2490698A4 (en) * | 2009-10-22 | 2013-09-25 | Hoffmann La Roche | MODULATION OF AXONES DEGENERATION |
| WO2014018932A2 (en) * | 2012-07-27 | 2014-01-30 | Bunt Antonius Martinus Gustave | Effluz inhibitor compositions and methods of treatment using the same |
-
2015
- 2015-09-24 GB GBGB1516905.5A patent/GB201516905D0/en not_active Ceased
-
2016
- 2016-09-23 AU AU2016329005A patent/AU2016329005A1/en not_active Abandoned
- 2016-09-23 US US15/762,657 patent/US20180263992A1/en not_active Abandoned
- 2016-09-23 MA MA042930A patent/MA42930A/fr unknown
- 2016-09-23 WO PCT/GB2016/052970 patent/WO2017051188A1/en not_active Ceased
- 2016-09-23 JP JP2018516056A patent/JP6893917B2/ja not_active Expired - Fee Related
- 2016-09-23 CA CA2999390A patent/CA2999390A1/en not_active Abandoned
- 2016-09-23 MX MX2018003619A patent/MX2018003619A/es unknown
- 2016-09-23 BR BR112018005855A patent/BR112018005855A2/pt not_active Application Discontinuation
- 2016-09-23 KR KR1020187010855A patent/KR20180056695A/ko not_active Withdrawn
- 2016-09-23 EA EA201890647A patent/EA201890647A1/ru unknown
- 2016-09-23 EP EP16775842.4A patent/EP3352759A1/en not_active Withdrawn
- 2016-09-23 CN CN201680056062.1A patent/CN108025005A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA42930A (fr) | 2018-08-01 |
| CA2999390A1 (en) | 2017-03-30 |
| GB201516905D0 (en) | 2015-11-11 |
| US20180263992A1 (en) | 2018-09-20 |
| JP2018534259A (ja) | 2018-11-22 |
| KR20180056695A (ko) | 2018-05-29 |
| EA201890647A1 (ru) | 2018-09-28 |
| JP6893917B2 (ja) | 2021-06-23 |
| EP3352759A1 (en) | 2018-08-01 |
| AU2016329005A1 (en) | 2018-04-19 |
| WO2017051188A1 (en) | 2017-03-30 |
| BR112018005855A2 (pt) | 2018-10-16 |
| CN108025005A (zh) | 2018-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018003619A (es) | Tratamiento de enfermedades neurodegenerativas. | |
| PH12019500204A1 (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| AU2019268063A1 (en) | Compositions for modulating sod-1 expression | |
| ZA201804513B (en) | Method of treating c3 glomerulopathy | |
| PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
| MX376201B (es) | Compuestos inhibidores de metaloenzima. | |
| PH12016501307B1 (en) | Compounds | |
| PH12017501990B1 (en) | Imidazopyrazinones as pde1 inhibitors | |
| MX2015012428A (es) | Tratamiento contra enfermedades mediadas th2 por inhibicion de bromodominios. | |
| HK1252425A1 (zh) | 用於治疗脱髓鞘疾病的三唑类药物 | |
| MX2016014396A (es) | Preparacion de enjuague bucal mejorada. | |
| WO2019173795A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| BR112018001907A2 (pt) | uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica | |
| PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
| EA201691057A1 (ru) | Новые способы лечения нейродегенеративных заболеваний | |
| PH12016501938A1 (en) | Halogenated quinazolin-thf-amines as pde1 inhibitors | |
| PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
| NZ729803A (en) | A method for the treatment of motor neuron diseases | |
| NZ724799A (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders |